Drug Trial Radar · NCT03533283
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
May 8, 2018
Primary completion
Oct 22, 2026
Study completion Oct 22, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.
Conditions
- Non-Hodgkins Lymphoma
Interventions
GlofitamabDrug
Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
AtezolizumabDrug
Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
ObinutuzumabDrug
Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
TocilizumabDrug
Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Polatuzumab VedotinDrug
Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
89Zr-Df-IAB22M2CDrug
Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Objective Response Rate (ORR) as Measured by Independent Review Committee (IRC)Time frame: Baseline until the end of treatment (13 to 14 months), then ever 3 months until end of study visit (to occur within 4 weeks of disease progression)
- Dose Limiting Toxicities (DLTs)Time frame: Atezolizumab Arm: During DLT period of 21 days (or up to 42 days in the case of cycle delay), starting on Day 1, Cycle 2; Polatuzumab Vedotin Arm: During 5-week DLT period starting Cycle 1, Day 8
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Novant Health Cancer Institute
Charlotte, North Carolina
UZ Gent
Ghent, Belgium
Aarhus Universitetshospital Skejby
Aarhus N, Denmark
Rigshospitalet
København Ø, Denmark
Odense Universitetshospital
Odense C, Denmark
Hadassah Ein Karem Hospital
Jerusalem, Israel
Rabin Medical Center-Beilinson Campus
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Istituto Nazionale Tumori Irccs Fondazione g. Pascale
Naples, Campania, Italy
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, Italy
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Duran i Reynals
Barcelona, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria
Málaga, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
The HOPE Clinical Trials Unit
Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.